Aims n-3 Polyunsaturated fatty acids (PUFAs) are known to protect the cardiovascular system and improve blood pressure control. These important dietary constituents are converted into bioactive metabolites, but their role in regulation of the cardiovascular system is unclear. In particular, the functions of the cytochrome P450 (CYP) metabolites of n-3 PUFAs remain virtually unexplored. In this study, we examined the effects of docosahexaenoic acid (DHA) on the regulation of large-conductance calcium-activated potassium (BK) channel activities in coronary arterial smooth muscle cells.
Introduction
Consumption of n-3 polyunsaturated fatty acids (PUFAs) in the diet or as a supplement is known to be associated with beneficial cardiovascular effects.
1,2 Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are the major n-3 PUFAs in fatty fish and are the recommended fish oil supplements endorsed by the American Heart Association for patients with coronary heart disease and hypertriglyceridaemia. 3 Although both DHA and EPA bestow protective effects on the cardiovascular system, DHA is more abundant than EPA in the human myocardium, 4 and DHA supplementation may be of greater therapeutic value than EPA because it produces more favourable results on lipid profile, 5 thrombotic risk, 6 and ambulatory blood pressure. 7 Like n-6 PUFAs, n-3 PUFAs are converted by multiple enzymatic pathways into bioactive products. In fact, DHA and EPA are competitive substrates for the enzymes of arachidonic acid (AA) metabolism. 8 Eicosapentaenoic acid is metabolized by the cyclo-oxygenase pathway into 3-series prostaglandins and thromboxanes, and by 5-lipoxygenase into 5-series leukotrienes, whereas DHA is metabolized into other autocoids, such as resolvins, docosatienes, and neuroprotectins. 8 More recently, EPA and DHA have been shown to be metabolized by cytochrome P450 (CYP) epoxygenase into fatty epoxides. 9 While the CYP products of AA have been extensively studied, very little is known about the function of the CYP products of DHA and EPA. The CYP products of AA metabolism are known as epoxyeicosatrienoic acids (EETs), which are endothelium-derived hyperpolarizing factors that produce potent vasodilatory effects. One of their major targets is the large-conductance Ca 2+ -activated K + (BK) channel. 10 In this study, we tested the hypothesis that the CYP products of DHA metabolism activate vascular BK channels to produce vasodilatation.
Methods

Materials
Chemicals were obtained from Sigma-Aldrich Chemical Co. (St. Louis, Missouri, USA), except DHA, 16,17-epoxydocosapentaenoic acid (16, , and 14,15-epoxyeicosa-5(Z)-enoic acid (14, , which were obtained from Cayman Chemical (Ann Arbor, Michigan, USA), and SKF525A from BIOMOL (Plymouth Meeting, Pennsylvania, USA). . All compounds were added abluminally. During the 60 min equilibration period, some vessels were pre-treated with b-diethyl-aminoethyldiphenylpropylacetate (SKF525A, 10 mM), N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MS-PPOH, 10 mM), ryanodine (10 mM), diltiazem (10 mM), or iberiotoxin (IBTX, 100 nM). Vessels were constricted with ET-1 ( 10 29 M) by 50-70% of baseline passive diameter.
Animals
Concentration-response relationships of DHA (0.1-10 mM) on vasodilatation were measured and comparisons made between those with and without pre-treatment with designated compounds. To assess the direct effects of the CYP epoxygenase products of DHA, concentration-response relationships of 16,17-EpDPE (0.1-50 nM) on vasodilatation were obtained. At the end of each experiment, vessels were maximally dilated with a Ca 2+ -free solution, and the percentage dilatation in response to DHA and to 16,17-EpDPE were normalized to the maximal diameter.
Isolation of rat coronary arterial smooth muscle cells
Rat coronary arterial smooth muscle cells (CASMCs) were dissociated enzymatically, as described previously. 12 
Spontaneous transient outward current recordings
Spontaneous transient outward currents (STOCs) were recorded from freshly isolated rat CASMCs at 0 mV for 2 min as whole-cell currents measured in the perforated-patch configuration as previously described. 13 Events of STOC openings were analysed using Clampfit 10.2 software (Molecular Devices, Inc., Sunnyvale, California, USA) before and after applications of 1 mM DHA and 0.1 mM IBTX. The frequency of STOCs was calculated as the total number of events divided by the recording time. The pipette and bath solutions were the same as those for wholecell BK channel recordings, except the pipette solution contained 50 -100 mM nystatin and the pipette tip was back-filled with pipette solution without nystatin to allow gigaseal formation.
13,14
Statistical analysis
Data are presented as means + SEM. Student's unpaired t-test was used to compare data between two groups. Student's paired t-test was used to compare data before and after treatment. A one-way ANOVA followed by contrast testing was used to compare data from multiple groups. Statistical significance was defined as P , 0.05.
Results
Effects of DHA on K 1 currents in rat CASMCs
Docosahexaenoic acid is a potent activator of K + currents in freshly isolated CASMCs. At baseline, CASMCs exhibited low levels of outward currents. Upon exposure to 1 mM DHA, the currents were enhanced several-fold, and these effects were reversed upon washout ( Figure 1A) . The time course of the DHA effects is shown in Figure 1B . Figure 1C shows the current -voltage (I-V) relationships of K + currents at baseline, with DHA, and after washout.
BK channels are major targets of DHA activation
To determine the composition of K + currents in rat CASMCs, we examined the effects of various ion channel blockers on the K + currents in rat CASMCs. These included the BK channel-specific blocker IBTX (100 nM), the intermediate conductance Ca currents. Figure 1D shows representative current traces at baseline and after application of specific K + channel blockers with the currents elicited from a HP of 260 mV and TP of 100 mV. Group data are summarized in Figure 1E . 
DHA is a potent activator of BK currents in rat CASMCs
We measured the effects of DHA on whole-cell BK currents in freshly isolated rat CASMCs with 5 mM 4AP, 1 mM APA, and 200 nM TRAM-34 in the bath solution to eliminate the Kv, SK, and IK currents in these cells, and to allow BK currents to be determined. Docosahexaenoic acid activated the BK currents in a concentration-dependent manner. Representative raw current traces are displayed in Figure 2A (left panel, HP ¼ 260 mV, TP ¼ 100 mV). Docosahexaenoic acid had no effects on BK currents at concentrations of 0.01 and 0.03 mM, but increased BK currents by 5 + 3, 170 + 69, and 220 + 73% at 0.1, 0.3, and 1.0 mM DHA, respectively (n ¼ 7, Figure 2A ). Curve fitting of individual concentration-response curves showed that DHA is a potent activator of BK currents with a half-maximal effective concentration (EC 50 ) of 0.23 + 0.03 mM ( Figure 2C ). The effects of DHA were inhibited by 100 nM IBTX, indicating that BK channels are the major target of the DHA effects ( Figure 2D ).
Effects of DHA on BK currents in CASMCs are dependent on CYP
To determine the role of CYP on the effects of DHA in BK channel activation, freshly isolated rat CASMCs were pre-treated for 60 min with 10 mM SKF525A, a CYP inhibitor. Unlike other commonly used CYP inhibitors, such as miconazole, we found that SKF525A does not have off-target effects that may interfere with interpretation of results. 18 The effects of DHA on BK channel activation (HP ¼ 260 mV, TP ¼ 100 mV) were virtually abolished after incubation with SKF525A (n ¼ 6, P , 0.05 vs. control conditions, Figure 2B and C). SKF525A by itself had no effect on the BK currents in CASMCs ( Figure 2E ). After pre-incubating the rat CASMCs with 10 mM MS-PPOH, another commonly used CYP inhibitor, DHA failed to activate BK currents, similar to the results after SKF525A preincubation ( Figure 2F ). These findings suggest that activation of BK channels by DHA in CASMCs is dependent on CYP activity at the concentrations studied.
16,17-EpDPE is a potent activator of BK currents in CASMCs
We examined the effects of 16,17-EpDPE, a DHA epoxide and a CYP epoxygenase product of DHA, on BK currents in CASMCs and found that applied in the extracellular solution 16,17-EpDPE is a potent activator of IBTX-sensitive BK currents. Exposure to 20 nM 16,17-EpDPE produced a significant increase in BK currents ( Figure 3A and B) . The effects of 16,17-EpDPE on the BK channel I-V relationships are shown in Figure 3C (HP ¼ 260 mV, TP ¼ 240 to 160 mV, n ¼ 4). The effects of 16,17-EpDPE were significant at TP . 100 mV (P , 0.05) as indicated. The effects of 16,17-EpDPE were IBTX sensitive and not affected by SKF525A pre-incubation ( Figure 3D and E), suggesting that BK channels are the major targets of 16,17-EpDPE activation. In a dose-dependent manner, 16,17-EpDPE potently activated the BK currents with an EC 50 of 19.7 + 2.8 nM (n ¼ 6; Figure 4F and G), indicating that this CYP epoxygenase product of DHA metabolism is a potent vascular BK channel activator.
Mechanisms of BK channel activation by DHA
We further determined the mechanism through which DHA and DHA epoxide activates BK channels. First, we examined whether the effects of 16,17-EpDPE were mediated through mechanisms similar to those of EETs by using the EET antagonist, 14,15-EEZE.
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After pre-incubation with 14,15-EEZE (500 nM), 16,17-EpDPE (500 nM) was able to activate the BK currents significantly, doubling the current density ( Figure 4A ), suggesting that BK channel activation by EpDPE is different from its n-6 PUFA epoxide counterpart. Next, we tried to determine whether DHA would enhance the activity of STOCs. Exposure to 1 mM DHA increased the frequency of STOCs in rat CASMCs 4.6-fold, from 121 + 47 events/min at baseline to 552 + 235 events/min (n ¼ 5, P , 0.05 vs. baseline), and the STOCs were inhibited by 100 nM IBTX (71 + 41 events/min), indicating the source of these currents to be BK channels ( Figure 4B ). These results suggest that activation of BK currents by DHA may be mediated through an increase in local Ca 2+ concentration, i.e. Ca 2+ sparks.
DHA-mediated dilatation of rat coronary arteries is CYP dependent
To determine the physiological relevance of these findings, we examined the effects of DHA on the dilatation of isolated rat small coronary arteries using videomicroscopy. 11 Docosahexaenoic acid produced dose-dependent vasodilatation of vessels pre-constricted with ET-1, producing dilatations of 0.5 + 0.5% at 0.1 mM, 8.1 + 1.8% at 0.5 mM, 22.6 + 2.8% at 1 mM, 27.3 + 2.6% at 5 mM, and 29.8 + 2.9% at 10 mM DHA. Docosahexaenoic acid is a potent vasodilator with an EC 50 of 0.67 + 0.07 mM (n ¼ 7), but it has only limited efficacy, as its effects plateaued at 30% vasodilatation ( Figure 5A ).
To determine the contribution of the CYP pathway to the effects of DHA-mediated vasodilatation, freshly isolated rat coronary arteries were incubated with 10 mM SKF525A for 60 min before the effects of DHA were measured. Incubation with SKF525A not only eliminated DHA-induced vasodilatation but also produced a 3.5 + 1.1% vasoconstriction by 10 mM DHA (n ¼ 4, P ¼ NS, Figure 5A ). These results indicate that all the vasodilatory effects of DHA were mediated through CYP metabolites.
To determine the role of BK channels in mediating the DHA-induced vasodilatation, rat coronary arteries were incubated with 100 nM IBTX for 30 min before the effects of DHA were measured. After incubation with IBTX, the effects of DHA were abolished (n ¼ 4, Figure 5A ). These results indicate that the vasodilatory effects of DHA were mediated through activation of BK channels. Pre-incubation of the vessels with both SKF525A and IBTX resulted in vasoconstriction in response to DHA ( Figure 5A ). Pre-incubation with another CYP epoxygenase inhibitor, MS-PPOH (10 mM), produced results similar to those with SKF525A ( Figure 5A ). These results confirmed that the vasodilatory effects of DHA are associated with activation of BK channels and that the CYP pathway is critical for DHA-mediated vasodilatation.
To further determine the mechanism through which DHA produces vasodilatation in rat coronary arteries, we examined the effects of ryanodine, which inhibits the Ca 2+ release channels in the sarcoplasmic reticulum. After pre-incubation with ryanodine (10 mM) for 10 min, DHA could no longer dilate rat coronary arteries ( Figure 5B) . Likewise, after pre-incubation with diltiazem (10 mM) for 30 min, which did not produce maximal vasodilatation, the DHAmediated vasodilatation was significantly blunted ( Figure 5B ). These results suggest that DHA may exert its effects through modulation of intracellular Ca 2+ homeostasis in CASMCs.
16,17-EpDPE is a potent vasodilator
To confirm that the DHA effects on vasodilatation are mediated through its CYP epoxygenase products of metabolism, we measured the effects of 16,17-EpDPE on the reactivity of isolated rat coronary arteries. The 16,17-EpDPE produced potent and dose-dependent vasodilatations of 5.1 + 1.9% at 0.1 nM, 10.6 + 1.8% at 0.5 nM, 23.6 + 1.0% at 1 nM, 29.7 + 1.1% at 5 nM, 31.5 + 1.1% at 10 nM, and 32.5 + 0.8% at 50 nM (n ¼ 6). The EC 50 for 16,17-EpDPE was 0.76 + 0.07 nM (n ¼ 6), reaching a plateau effect of about 30% vasodilatation at concentrations around 3 nM ( Figure 6 ).
To determine the role of BK channels in mediating the 16,17-EpDPE-induced vasodilatation, rat coronary arteries were incubated with 100 nM IBTX for 30 min before the effects of 16,17-EpDPE were measured. After incubation with IBTX, the effects of 16,17-EpDPE were abolished (n ¼ 4, Figure 6A ). These results indicate that the vasodilatory effects of 16,17-EpDPE were mediated through activation of BK channels. In addition, pre- . Upon exposure to 1 mM DHA, K + currents were activated three-fold, and the DHA-activated currents were sensitive to IBTX (100 nM). (E) Acute exposure to SKF525A (10 mM) had no effect on the IBTX-sensitive currents in CASMCs. (F) After pre-treatment with MS-PPOH (10 mM), DHA could no longer activate BK currents, confirming that the effects of DHA were dependent on the CYP epoxygenase activities.
incubation with ryanodine completely abolished the 16,17-EpDPE-mediated vasodilatation ( Figure 6A) , while preincubation with SKF525A (10 mM for 30 min) had no effect ( Figure 6B) . These results are in agreement with the effects of DHA on rat coronary artery vasodilatation and with the effects of DHA and 16,17-EpDPE on BK channel activation. Together, our findings suggest that the CYP epoxygenase metabolites of DHA, namely the DHA epoxides, play an important physiological role in the regulation of coronary arterial tone through modulation of vascular BK channels.
Discussion
In this study, we have reported several important findings. First, DHA activates BK channels in rat CASMCs at sub-micromolar levels with an EC 50 of 0.23 mM. Secondly, DHA-mediated vascular BK channel activation is dependent on the activity of the CYP pathway. Thirdly, the DHA effects on BK channel activation were reproduced by 16,17-EpDPE, a CYP epoxygenase product of DHA metabolism. Fourthly, DHA dilates isolated rat coronary arteries at submicromolar levels with an EC 50 of 0.67 mM, and these effects were Activation of BK channels by docosahexaenoic acid completely dependent on the activities of the CYP pathway. Fifthly, the effects of DHA-mediated vasodilatation were reproduced by 16,17-EpDPE. Sixthly, DHA activates STOCs, and DHA-and 16,17-EpDPE-mediated vasodilatation were abolished by ryanodine. These findings suggest that DHA is an important modulator of vascular function, producing potent vasodilatation through activation of BK channels in vascular smooth muscle cells by its CYP epoxygenase metabolites, which may modulate intracellular Ca 2+ homeostasis.
A multitude of cellular and physiological mechanisms have been proposed through which n-3 PUFAs exert their beneficial effects, 1, 2 including reduced platelet aggregation, anti-inflammatory effects, reduced plasma triglycerides, improved autonomic function, direct membrane effects and modulation of ion channel function, and improved vascular endothelial function. Our finding that DHA is a potent activator of the vascular BK channels delineates a basic mechanism through which n-3 PUFAs provide cardiovascular protective effects by serving as vasodilators to modulate systemic blood pressure and to improve tissue perfusion.
Docosahexaenoic acid has been shown to inhibit numerous ion channels, such as the cardiac voltage-gated sodium currents, the L-type Ca 2+ currents, the T-type Ca 2+ currents, delayed rectifier K + currents, and the transient outward K + currents. 15, 16 It is intriguing that DHA uniformly inhibits the cardiac currents, whereas it activates vascular BK currents. As BK channels are major determinants of vascular tone, activation of BK channels causes hyperpolarization of membrane potentials, which leads to the closing of voltage-gated Ca 2+ currents and subsequent vasorelaxation. 17 Since human plasma concentrations of DHA are in the micromolar range, 20 our finding that BK currents are activated by sub-micromolar concentrations of DHA suggests that these effects are physiologically relevant and that important vascular beds, including the coronary vasculature, may be significantly regulated by DHA and its metabolites. Like the n-6 PUFAs, n-3 PUFAs are metabolized by similar enzymes and pathways. 8 Our findings that DHA-mediated BK channel activation and coronary vasodilatation are CYP dependent are similar to those reported for n-6 PUFAs, such as AA. Indeed, the CYP epoxygenase metabolites of AA, EETs, are known endothelium-derived hyperpolarizing factors that activate BK channels. 21, 22 Both EETs and 16,17-EpDPE activate vascular BK channels and produce significant coronary vasodilatation in the nanomolar range. However, in contrast to the AA-mediated effects on BK channels and vasodilatation, which The STOCs in CASMCs were recorded at 0 mV in whole-cell recordings using the perforated patch technique. Exposure to 1 mM DHA increased the frequency of STOCs by 4.6-fold, and this was inhibited by 100 nM IBTX to below baseline values, suggesting that the source of these currents was from BK channels. Figure 5 Effects of DHA on dilatation of isolated rat coronary arteries. (A) DHA produced potent dose-dependent dilatation of rat coronary arteries with an EC 50 of 0.67 + 0.07 mM. However, after incubation with the CYP inhibitor SKF525A (10 mM for 60 min, n ¼ 4), MS-PPOH (10 mM for 60 min, n ¼ 6), IBTX (100 nM for 30 min, n ¼ 4), or with SKF + IBTX (n ¼ 3), the vasodilatory effects of DHA were totally abolished (n ¼ 4). (B) After pretreatment with ryanodine (10 mM for 10 min, n ¼ 6), or with diltiazem (10 mM for 30 min, n ¼ 6), the ability of DHA to produce vasodilatation in isolated rat coronary arteries was abolished.
were only partly reduced by CYP inhibitors, 11 the effects of DHA were totally abolished by the CYP inhibitors, SKF525A and MS-PPOH. The difference may be because AA is metabolized into many bioactive metabolites by multiple enzymatic pathways, including cyclo-oxygenase, lipoxygenase, and the CYP epoxygenase. 23 Inhibition of CYP thus only partly suppresses the production of the AA metabolites. In contrast, DHA is a poor substrate for cyclo-oxygenase and lipoxygenase, 24 and at 1 mM DHA, only CYP epoxygenase produces significant bioactive metabolites. The effects of DHA were not inhibited by 14,15-EEZE, which antagonizes the effects of EET through specific binding to the putative EET receptor. 19, 25 Our results indicate that 16,17-EpDPE activates vascular BK channels through mechanisms that are different from its n-6 PUFA counterparts. Very little is known about the DHA-derived epoxides. Epoxygenase metabolites of DHA have been shown to inhibit platelet aggregation with a half-maximal inhibitory concentration of 0.7 -1.5 mM. 26 Our results demonstrated that 16,17-EpDPE is a potent vascular BK channel activator. In addition, we showed that the DHA effects were exclusively dependent on CYP activity, indicating that the CYP epoxygenase products of DHA may be important dietary regulators of vascular functions. Recently, among 15 human recombinant CYPs examined, CYP2C9, CYP2C19, and CYP1A2 were found to be the most efficient in DHA epoxidation, equal to or more efficient in epoxidizing DHA than AA. 9 Since the CYP2C enzymes are abundantly expressed in the vasculature, 27 the production of EpDPEs and their role in the regulation of vascular function may depend on DHA availability. The mechanism through which the CYP metabolites of DHA activate vascular BK channels is not entirely clear. Our findings that DHA promotes the development of STOCs and that ryanodine inhibits the vasodilatory effects of DHA and 16,17-EpDPE suggest that the DHA metabolites may facilitate Ca 2+ release from the sarcoplasmic reticulum, possibly through regulation of calcium sparks. 28 Indeed, the Ca 2+ channel, ryanodine receptors, and BK channels operate as a functional unit in the regulation of vascular tone, 13 and our findings ( Figures 4B,   5B , and 6A) are consistent with this scheme. However, these properties of DHA metabolites are different from 17,18-epoxyeicosatetranoic acid, the CYP epoxygenase product of EPA, which activates the vascular BK channels independent of intracellular Ca 2+ concentration or local sarcoplasmic reticulum Ca 2+ release events. 29 The difference in properties of these metabolites might explain in part the difference in outcomes and effects between DHA and EPA. As accumulating evidence establishes the cardiovascular protective roles of n-3 PUFAs, the DHA metabolites bear great significance in mediating these effects. Our present findings have helped demonstrate the role of CYP and EpDPE in mediating the vascular protective effects of DHA. Mechanistic delineation of the cardiovascular function of these important DHA metabolites may provide further insights into the beneficial effects n-3 PUFAs. 
